Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials

Abstract

AimTo conduct a meta‐analysis of randomized clinical trials (RCTs) to investigate whether there is an association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) treatment and thyroid cancer.Materials and MethodsIn this meta‐analysis of RCTs, we included studies comparing a GLP‐1RA with any comparator, lasting at least 52 weeks, and reporting the incidence of adverse events independently of the principal endpoint and population. All cases of thyroid cancer were collected.ResultsWe retrieved 64 trials, 26 of which reported at least one incident case of thyroid cancer. GLP‐1RA treatment was associated with a significant increase in the risk of overall thyroid cancer (Mantel‐Haenzel odds ratio [MH‐OR] 1.52 [95% confidence interval {CI} 1.01, 2.29]; P = 0.04, I2 = 0%), with a fragility index of 1, and a 5‐year number needed to harm of 1349. The association remained significant when including only trials lasting at least 104 weeks (MH‐OR 1.76 [95% CI 1.00, 3.12]; P = 0.05). No significant association was found for papillary thyroid cancer (MH‐OR 1.54 [95% CI 0.77, 3.06]; P = 0.22) or medullary thyroid cancer (MH‐OR 1.44 [95% CI 0.23, 9.16]; P = 0.55).ConclusionsOur meta‐analysis showed that GLP‐1RA treatment could be associated with a moderate increase in relative risk for thyroid cancer in clinical trials, with a small increase in absolute risk. Studies of longer duration are required to assess the clinical implications of this finding.

Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials

“…The present meta-analysis is a post-hoc analysis of a currently ongoing systematic review, 13 previously registered on PROSPERO (https://www.crd.york.ac.uk/PROSPERO, CRD42023456382). A Medline, Embase, Clinicaltrials.gov and Cochrane CENTRAL Database search was performed up to 10 December 2023, as detailed in Table S1.…”

Exploring the Unintended Consequences of Misuse of Wegovy and Ozempic in Weight Management: A Comprehensive Review

“…Other warnings include the risk of pancreatitis, acute kidney injury, and hypersensitivity reactions. Ozempic pens should never be shared between patients to prevent the transmission of blood-borne pathogens [12].…”

Implications of GLP-1 Receptor Agonist on Thyroid Function: A Literature Review of Its Effects on Thyroid Volume, Risk of Cancer, Functionality and TSH Levels

“…Silverii et al [ 62 ], with a meta-analysis of RCTs examining 64 studies, wanted to investigate the association between treatment with GLP-1 RAs and the onset of thyroid cancer. Treatment with GLP-1 RAs was found to be significantly associated with an increased overall risk of thyroid carcinoma (Mantel–Haenszel odds ratio [MH-OR] 1.52 95% CI 1.01–2.29; p = 0.04, I 2 = 0%).…”